Marker Therapeutics Inc (MRKR)

[scion]

Genemax Corp · NT 10-K · For 12/31/2
Filed On 4/1/3 · SEC File 0-27239 · Accession Number 1050502-3-285
As Of Filer Filing On/For/As Ds:Ps Subject Agent

4/01/03 Genemax Corp NT 10-K 4/01/03 1:3 1050502


--------------------------------------------------------------------------------

Notice of a Late Filing of Form 10-K or 10-KSB · Form 12b-25
Filing Table of Contents
Document/Exhibit Description Pages Bytes

1: NT 10-K Notice of a Late Filing of Form 10-K or 10-KSB 3 9K

NT 10-K 1st Page of 3 TOC Top Previous Next Bottom Just 1st

U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 12b-25

NOTIFICATION OF LATE FILING
(Check One):

[X] Form 10KSB [ ] Form 20F [ ] Form 11K [ ] Form 10QSB [ ] Form N-SAR

For Period Ended: December 31, 2002

[ ] Transition Report on Form 10-KSB
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-QSB
[ ] Transition Report on Form N-SAR

For the Transition Period Ended:

Read Attached Instruction Sheet Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:

Not applicable.

--------------------------------------------------------------------------------

PART I - REGISTRANT INFORMATION
--------------------------------------------------------------------------------

Full Name of Registrant: GeneMax Corp.

Former Name if Applicable:

Address of Principal Executive
Office (Street and Number): 435 Martin Street, Suite 2000

City, State and Zip Code: Blaine, Washington 98230

--------------------------------------------------------------------------------

PART II - RULES 12b-25(b) and (c)
--------------------------------------------------------------------------------

If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)

[ ] (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;

[X] (b) The subject annual report, semi-annual report, transition report on
Form 10-KSB, Form 20-F, 11-K or Form N-SAR, or portion thereof will be
filed on or before the fifteenth calendar day following the prescribed
due date; or the subject quarterly report or transition report on Form
10-QSB, or portion thereof will be filed on or before the fifth
calendar day following the prescribed due date; and

[ ] (c) The accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.

NT 10-K 2nd Page of 3 TOC 1st Previous Next Bottom Just 2nd

-----------------------------------------------------------------------

PART III - NARRATIVE
-----------------------------------------------------------------------

State below in reasonable detail the reasons why the Form 10-KSB, 20-F, 11-K,
10-QSB or N-SAR or the transition report or portion thereof could not be filed
within the prescribed period.

GeneMax Corp. (formerly known as "Eduverse.com"), a Nevada corporation (the
"Company"), recently acquired GeneMax Pharmaceuticals, Inc. pursuant to a share
exchange agreement (the "Share Exchange Agreement"). The consummation of the
transaction has been reported in prior 8-K filings and in the Quarterly Report
on Form 10-QSB for nine- month period ended September 30, 2002.

The consummation of the Share Exchange Agreement has raised certain complex
accounting issues. Preparation of the Company's Annual Report on Form 10-KSB for
fiscal year ended December 31, 2002 includes for the first time audited
consolidated financial statements since consummation of the Share Exchange
Agreement. Management of the Company deems that additional time is necessary in
order for the Company to properly address such accounting issues in connection
with the acquisition of GeneMax Pharmaceuticals, Inc., to properly prepare its
financial statements and footnotes for fiscal year ended December 31, 2002, and
to ensure complete and thorough and accurate disclosure of all material facts in
the Annual Report. Management anticipates completion of the audited consolidated
financial statements and the filing of its Annual Report on Form 10-KSB by April
15, 2003.

--------------------------------------------------------------------------------

PART IV - OTHER INFORMATION
--------------------------------------------------------------------------------

(1) Name and telephone number of person to contact in regard to this
notification: Diane D. Dalmy 303.985.9324.

(2) Have all other period reports required under section 13 or 15(d) of the
Securities Exchange Act of 1934 or section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such reports(s) been filed? If the answer
is no, identify report(s).

[X] Yes [ ] No.

(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof?

[ ] Yes [X] No

If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.

--------------------------------------------------------------------------------

NT 10-K Last Page of 3 TOC 1st Previous Next Bottom Just 3rd

GENEMAX CORP.
--------------------------------
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.

Date: April 1, 2003 By: /s/ Ronald Handford
----------------------------
Ronald Handford, President and Chief
Executive Officer

INSTRUCTION: The form may be signed by an executive officer of the registrant or
by any other duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If the
statement is signed on behalf of the registrant by an authorized representative
(other than an executive officer), evidence of the representative's authority to
sign on behalf of the registrant shall be filed with the form.

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal
Violations (See 18 U.S.C. 1001)
http://www.secinfo.com/d1Z1S9.28y.htm